2617 Bissonnet Street
Suite 225
Houston, TX 77005
United States
346 355 4099
https://www.alaunos.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 1
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Dale Curtis Hogue Jr. | Interim CEO & Director | N/A | N/A | 1970 |
Ms. Melinda Lackey | Senior VP of Legal, Administration & Secretary | 625.12k | N/A | 1977 |
Mr. Michael Wong | Vice President of Finance & Principal Accounting Officer | N/A | N/A | 1980 |
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.
Alaunos Therapeutics, Inc.’s ISS governance QualityScore as of 1 May 2024 is 6. The pillar scores are Audit: 9; Board: 6; Shareholder rights: 3; Compensation: 9.